Patents Assigned to Amgen
  • Modified Fc molecules
    Patent number: 7655764
    Abstract: The present invention concerns compositions of matter, for example, but not limited to, modified antibodies, in which one or more biologically active peptides are incorporated into a loop region of a non-terminal domain of an immunoglobulin Fc domain.
    Type: Grant
    Filed: August 1, 2008
    Date of Patent: February 2, 2010
    Assignee: Amgen Inc.
    Inventors: Colin Gegg, Fei Xiong, Karen C. Sitney
  • Antagonists of Interleukin-15
    Publication number: 20100015723
    Abstract: Antagonists of mammalian interleukin-15 (“IL-15”) are disclosed and include muteins of IL-15 and modified IL-15 molecules that are each capable of binding to the IL-15R?-subunit and that are incapable of transducing a signal through either the ?- or ?-subunits of the IL-15 receptor complex. Also included are monoclonal antibodies against IL-15 that prevent IL-15 from effecting signal transduction through either the ?- or ?-subunits of the IL-15 receptor complex. Methods of treating various disease states are disclosed, including treating allograft rejection and graft-versus-host disease.
    Type: Application
    Filed: May 23, 2007
    Publication date: January 21, 2010
    Applicants: Amgen Inc., IMMUNEX CORPORATION
    Inventors: Kenneth H. Grabstein, Dean K. Pettit, Raymond J. Paxton
  • Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
    Patent number: 7649110
    Abstract: The present invention provides compounds useful, for example, for modulating insulin levels in a subject and that have the general formula Q—L1—P—L2—M—X—L3—A wherein the definitions of the variables Q, L1, P, L2, M, X, L3 and A are provided herein. The present invention also provides compositions and methods for use of the compounds, for instance, for treatment of type II diabetes.
    Type: Grant
    Filed: February 25, 2005
    Date of Patent: January 19, 2010
    Assignee: Amgen Inc.
    Inventors: Michelle Akerman, Jonathan Houze, Daniel C. H. Lin, Jinqian Liu, Jiwen Liu, Jian Luo, Zhihua Ma, Julio C. Medina, Wei Qiu, Jeffrey D. Reagan, Rajiv Sharma, Michael J. Schmitt, Stephen J. Shuttleworth, Ying Sun, Yingcai Wang, Jian Zhang, Liusheng Zhu
  • Tissue inhibitor of metalloproteinase type three (TIMP-3) composition and methods
    Publication number: 20100010201
    Abstract: The present invention relates in general to metalloproteinase inhibitors and to polynucleotides encoding such inhibitors. In particular, the invention relates to novel mammalian inhibitors of metalloproteinase, which are designated as type three or TIMP-3, to fragments, derivatives, and analogs thereof, and to polynucleotides encoding the same. Novel methods of producing such compositions and novel methods of using such compositions are also provided.
    Type: Application
    Filed: September 18, 2008
    Publication date: January 14, 2010
    Applicant: Amgen Inc.
    Inventors: Scott M. Silbiger, Raymond A. Koski
  • AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE
    Publication number: 20100010014
    Abstract: The invention relates to aminopyrimidine compounds useful for treating diseases mediated by polo-like kinase 1 (Plk1). The invention also relates to the therapeutic use of such aminopyrimidine compounds and compositions thereof in treating disease states associated with abnormal cell growth and unwanted cell proliferation.
    Type: Application
    Filed: September 18, 2009
    Publication date: January 14, 2010
    Applicant: Amgen Inc.
    Inventors: Adrian Leonard Smith, Paul Edward Brennan, Frenel Fils DeMorin, Gang Lin, Nick A. Paras, Daniel Martin Retz, Elizabeth Rainbeau
  • Linked biaryl compounds
    Patent number: 7645779
    Abstract: Compounds, compositions and methods that are useful for the treatment of metabolic disorders, inflammatory diseases and cancer are provided herein. In particular, the invention provides compounds which modulate the expression and/or function of proteins involved in lipid metabolism, inflammation and cell proliferation. The subject compounds are linked biaryl compounds.
    Type: Grant
    Filed: August 20, 2004
    Date of Patent: January 12, 2010
    Assignees: Amgen Inc., Japan Tobacco, Inc.
    Inventors: Hiroyuki Abe, Jonathan Houze, Hisashi Kawasaki, Frank Kayser, Rajiv Sharma, Samuel Sperry
  • Modified Fc molecules
    Patent number: 7645861
    Abstract: The present invention concerns compositions of matter, for example, but not limited to, modified antibodies, in which one or more biologically active peptides are incorporated into a loop region of a non-terminal domain of an immunoglobulin Fc domain.
    Type: Grant
    Filed: August 1, 2008
    Date of Patent: January 12, 2010
    Assignee: Amgen Inc.
    Inventors: Colin Gegg, Fei Xiong, Karen C. Sitney
  • Fibroblast Growth Factor-Like Polypeptides
    Publication number: 20090324599
    Abstract: The present invention provides novel Fibroblast Growth Factor-like (FGF-like) polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, antibodies and methods for producing FGF-like polypeptides. Also provided for are methods for the diagnosis and treatment of diseases associated with FGF-like polypeptides.
    Type: Application
    Filed: November 13, 2008
    Publication date: December 31, 2009
    Applicant: AMGEN INC.
    Inventors: Arlen Thomason, Benxian Liu
  • Fused heterocyclic derivatives and methods of use
    Publication number: 20090318436
    Abstract: Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Application
    Filed: October 14, 2008
    Publication date: December 24, 2009
    Applicant: Amgen Inc.
    Inventors: Brian K. Albrecht, David Bauer, Steven Bellon, Christiane M. Bode, Shon Booker, Alessandro Boezio, Deborah Choquette, Derin D'Amico, Jean-Christophe Harmange, Satoko Hirai, Randall W. Hungate, Tae-Seong Kim, Richard T. Lewis, Longbin Liu, Julia Lohman, Mark H. Norman, Michelle Potashman, Aaron C. Siegmund, Stephanie K. Springer, Markian Stec, Ning Xi, Kevin Yang
  • Benzimidazole derivatives
    Patent number: 7635774
    Abstract: Compounds, pharmaceutical compositions and methods are provided that are useful in the treatment of inflammatory and immune-related conditions or disorders. In particular, the invention provides compounds which modulate the expression and/or function of proteins involved in inflammation, immune response regulation and cell proliferation. The subject compounds are 2-amino-imidazole derivatives.
    Type: Grant
    Filed: August 30, 2006
    Date of Patent: December 22, 2009
    Assignee: AMGEN Inc.
    Inventors: Alexander David Frenkel, Sarah Elizabeth Lively, Jay P. Powers, Andrew Smith, Daqing Sun, Craig Tomooka, Zhulun Wang
  • Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
    Patent number: 7635715
    Abstract: Compounds of Formula I and Formula II are useful as inhibitors of HIF prolyl hydroxylases. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.
    Type: Grant
    Filed: December 17, 2007
    Date of Patent: December 22, 2009
    Assignee: Amgen Inc.
    Inventors: Jennifer R. Allen, Kaustav Biswas, Marian C. Bryan, Roland Burli, Guo-Qiang Cao, Michael J. Frohn, Jennifer E. Golden, Stephanie Mercede, Susana Neira, Tanya Peterkin, Alexander J. Pickrell, Anthony Reed, Christopher M. Tegley, Xiang Wang
  • Antiinflammation agents
    Patent number: 7635695
    Abstract: Compounds, compositions and methods that are useful in the treatment of inflammatory, immunoregulatory, metabolic, infectious and cell proliferative diseases or conditions are provided herein. In particular, the invention provides compounds which modulate the expression and/or function of proteins involved in inflammation, metabolism, infection and cell proliferation. The subject compounds contain a fused heterobicyclic ring.
    Type: Grant
    Filed: February 21, 2007
    Date of Patent: December 22, 2009
    Assignee: Amgen Inc.
    Inventors: Simon A. Burkitt, Mario G. Cardozo, Timothy D. Cushing, Michael R. DeGraffenreid, Christopher N. Farthing, Xiaolin Hao, Juan C. Jaen, Xian Yun Jiao, David J. Kopecky, Marc Labelle, Sarah E. Lively, Dustin L. McMinn, Sven P. Rasmussen, Youngsook Shin, Marie-Louise Smith, Andrew Smith
  • Osteoprotegerin
    Patent number: 7632922
    Abstract: The present invention discloses a novel secreted polypeptide, termed osteoprotegerin, which is a member of the tumor necrosis factor receptor superfamily and is involved in the regulation of bone metabolism. Also disclosed are nucleic acids encoding osteoprotegerin, polypeptides, recombinant vectors and host cells for expression, antibodies which bind OPG, and pharmaceutical compositions. The polypeptides are used to treat bone diseases characterized by increased resorption such as osteoporosis.
    Type: Grant
    Filed: November 22, 2000
    Date of Patent: December 15, 2009
    Assignee: Amgen, Inc.
    Inventors: William J. Boyle, David L. Lacey, Frank J. Calzone, Ming-Shi Chang
  • Wash Buffer And Method Of Using
    Publication number: 20090306351
    Abstract: A method for purifying a protein using Protein A chromatography comprising a) absorbing the protein to Protein A immobilized on a solid support; b) removing contaminants by washing the immobilized Protein A containing the absorbed protein with a buffer comprising one or more chaotropic agents in combination with one or more hydrophobic modifiers and having a pH of at least 7.0; and c) eluting the protein from the Protein A immobilized on the solid support.
    Type: Application
    Filed: March 16, 2007
    Publication date: December 10, 2009
    Applicant: Amgen Inc.
    Inventors: Abhinav A. Shukla, Peter Hinckley
  • BINDING AGENTS
    Publication number: 20090304713
    Abstract: Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided.
    Type: Application
    Filed: November 24, 2008
    Publication date: December 10, 2009
    Applicants: AMGEN INC., UCB PHARMA S.A.
    Inventors: Christoper Paszty, Martin Kim Robinson, Kevin Graham, Alistair James Henry, Kelly Sue Hoffmann, John Latham, Hsieng Sen Lu, Alastair Lawson, Andy Popplewell, Wenyan Shen, David G. Winkler, Aaron George Winters
  • FGF21 Mutants and uses thereof
    Publication number: 20090305986
    Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
    Type: Application
    Filed: June 3, 2009
    Publication date: December 10, 2009
    Applicant: Amgen Inc.
    Inventors: Edward John Belouski, Murielle Marie Ellison, Agnes Eva Hamburger, Randy Ira Hecht, Yue-Sheng Li, Mark Leo Michaels, Jeonghoon Sun, Jing Xu
  • Ang2 and Vegf Inhibitor Combinations
    Publication number: 20090304694
    Abstract: The invention provides methods for using Ang2 inhibitors in combination with VEGF inhibitors to treat disease. The invention also provides compositions, kits, formulations, and specific disease treatments relating thereto.
    Type: Application
    Filed: January 19, 2007
    Publication date: December 10, 2009
    Applicant: AMGEN INC.
    Inventors: Jonathan Oliner, Richard Kendall, Rakesh Kumar
  • Secreted epithelial colon stromal-1 molecules and uses thereof
    Patent number: 7629144
    Abstract: The present invention provides novel Secreted Epithelial Colon Stromal-1 (Secs-1) polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, selective binding agents, and methods for producing Secs-1 polypeptides. The invention further provides methods for the treatment, diagnosis, amelioration, or prevention of diseases associated with Secs-1 polypeptides.
    Type: Grant
    Filed: February 28, 2006
    Date of Patent: December 8, 2009
    Assignee: Amgen Inc.
    Inventors: Anthony J. Polverino, Roland Luethy
  • Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
    Patent number: 7628986
    Abstract: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.
    Type: Grant
    Filed: June 25, 2004
    Date of Patent: December 8, 2009
    Assignee: Amgen Fremont Inc.
    Inventors: Richard Weber, Xiao Feng, Orit Foord, Larry Green, Jean M. Gudas, Bruce Keyt, Ying Liu, Palaniswami Rathanaswami, Robert Raya, Xiao Dong Yang, Jose Corvalan, Ian Foltz, Xiao-Chi Jia, Jaspal S. Kang, Chadwick T. King, Scott L. Klakamp, Qiaojuan Jane Su
  • Thiadiazole modulators of PKB
    Publication number: 20090298836
    Abstract: The invention relates to thiazole compounds of Formula I and Formula II and compositions thereof useful for treating diseases mediated by protein kinase B (PKB) where the variables have the definitions provided herein. The invention also relates to the therapeutic use of such thiazole compounds and compositions thereof in treating disease states associated with abnormal cell growth, cancer, inflammation, and metabolic disorders.
    Type: Application
    Filed: July 15, 2008
    Publication date: December 3, 2009
    Applicant: Amgen Inc.
    Inventors: Qingping Zeng, Chester Chenguang Yuan, Guomin Yao, Xianghong Wang, Seifu Tadesse, Andreas Reichelt, Qingyian Liu, Matthew R. Lee, Xin Huang, Fang-Tsao Hong, Nianhe Han, Christopher H. Fotsch, Celia Dominguez, Matthew P. Bourbeau, John G. Allen